Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Manz

Showing results (181-190 of 184) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 184 results.
Journal of Internal Medicine|December 8, 2017
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemiaC Craddock, J Versluis, M Labopin, et al.
Leukemia|July 22, 2022
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndromeJ J W M Janssen, B Löwenberg, M Manz, et al.
Leukemia|February 6, 2020
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Leukemia|August 1, 2020
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Pageof 19

Showing results (181-190 of 184) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 184 results.
Journal of Internal Medicine|December 8, 2017
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemiaC Craddock, J Versluis, M Labopin, et al.
Leukemia|July 22, 2022
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndromeJ J W M Janssen, B Löwenberg, M Manz, et al.
Leukemia|February 6, 2020
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Leukemia|August 1, 2020
Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDSG J Ossenkoppele, D A Breems, G Stuessi, et al.
Pageof 19